FDA Breakthrough Therapy Designation Received by Merck for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease 글 내용 전체보기
Reviews for New Drug Application (NDA) for Merck’s Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA® (Ceftolozane and Tazobactam) Accepted by FDA 글 내용 전체보기
FDA Breakthrough Therapy Designation received by Novartis for their Investigational Therapy crizanlizumab (SEG101) for the Prevention of Vaso-Occlusive Crises in Sickle Cell Disease 글 내용 전체보기
Sanofi Announce Isatuximab Phase 3 Trial Meets Primary Endpoint of Prolonging Progression Free Survival in Patients with Relapsed/Refractory Multiple Myeloma 글 내용 전체보기
Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Securities 글 내용 전체보기
NLRB Dismisses St. Luke’s Union Election Complaint, Nurses Move Forward to Negotiate Patient Safety and Other Important Issues 글 내용 전체보기
Extreme Networks to Showcase the Hospital of the Future at HIMSS 2019 Intelligent Health Pavilion 글 내용 전체보기
DWC Announces Free Online Access to Evidence-Based Treatment Guidelines for Medical Providers 글 내용 전체보기
Civitas Senior Living and LKP Ventures Announce Development of New Luxury Senior Living Community for Roanoke 글 내용 전체보기
